Net Sales Margin: sunshinebiopharma.com (SBFM)

Corporate emblem and logo of Sunshine Biopharma (SBFM)

Sunshine Biopharma (SBFM) is susceptible to disruptions in global reagent supplies and geopolitical barriers during drug registration. The company's sales margins demonstrate current operational resilience, where the parameter equals -17.40. The development of a small-molecule platform to combat tumor resistance creates unique value, although liquidity shortages and early-stage research risks could lead to equity dilution.

Sunshine Biopharma, Inc. (SBFM) - Company Sales Margin from 07/04/2022 to 11/19/2026

Analytical breakdowns for Sunshine Biopharma

- market value and analyst target forecast:
Summary company analytics:Sunshine Biopharma, Inc. - SBFM
Flagship merchandise of Sunshine Biopharma Inc.

Net margin captures the portion of profit remaining with the business after covering all operating and financial obligations. This metric serves as a stress-testing tool for capital resilience against internal costs. The current sales margin level -17.40 reflects Sunshine Biopharma's critical dependence on external financing. A lack of pricing power and proprietary revenue streams renders this indicator negative. Investors should interpret such values as an indicator of venture risk inherent in clinical biotech.

Direct competitors

ONC: Net Sales Margin|Net Margin Halozyme Inc. (HALO)|Net Margin RevMed|Net Return on Sales AAPG (Ascentage Pharma Group)|Net Sales Margin CGON|UroGen Pharma - Net Return on Sales|Bicara Therapeutics - Return on Sales by Net Profit|Net Sales Margin Personalis Inc PSNL|Erasca Oncology - Net Sales Margin|Net Profit Rate DCTH (Delcath Corp)|YMAB: Net Sales Margin|AURA - Company Sales Margin|CADL (Candel Therapeutics Inc.) - Net Sales Margin|Net Return on Sales ARAY (Accuray)|Return on Sales by Net Profit SLS (SELLAS Life Sciences Group, Inc.)|ACTU - Net Margin|Net Margin Citius Oncology, Inc. CTOR|HURA - Return on Sales by Net Profit|protaratx.com - Net Sales Margin|FATE - Net Sales Margin|WHWK: Net Sales Margin|TScan Therapeutics (TCRX) - Net Sales Margin|Net Margin Champions Oncology|Net Margin XBIT|Net Sales Margin CVM|Return on Sales by Net Profit OS Therapies Inc. OSTX|Net Margin Radiopharm Theranostics Limited RADX|artivabio.com (ARTV) - Net Margin|ANL - Net Margin|Net Margin verupharma.com|TPST: Net Sales Margin|XLO - Company Sales Margin|Net Margin Renovaro|Net Sales Margin muraloncology.com|Net Sales Margin KAPA|Company Sales Margin OnKure Therapeutics, Inc.|Net Sales Margin GDTC (w2.cytomed.sg)|CRIS - Return on Sales by Net Profit|Apollomics - Net Sales Margin|Tharimmune Corp (THAR) - Return on Sales by Net Profit|ADVB: Net Sales Margin|Return on Sales by Net Profit Genprex|CLDI (Calidi Biotherapeutics, Inc.) - Net Sales Margin|Net Sales Margin xeneticbio.com|Net Margin Salarius (SLRX)|Return on Sales by Net Profit Purple Biotech PPBT|Net Margin American Oncology Network, Inc. AONC|BeiGene, Ltd. (BGNE) - Net Margin|Checkpoint Therapeutics Inc. - Net Sales Margin|Net Profit Rate ELEV (Elevation Oncology)|ICAD (iCAD Corp) - Return on Sales by Net Profit|Ikena Oncology, Inc. - Net Profit Rate|Return on Sales by Net Profit NTBL|VIRX: Net Profit Rate|Net Margin MorphoSys Corporation (MOR)|NAYA - Net Margin|Net Sales Margin AAPGV (Ascentage)